Detalles de la búsqueda
1.
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
BMC Cancer
; 24(1): 436, 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38589856
2.
Chemotherapy-Induced Changes in Plasma Amino Acids and Lipid Oxidation of Resected Patients with Colorectal Cancer: A Background for Future Studies.
Int J Mol Sci
; 25(10)2024 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38791339
3.
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.
Br J Cancer
; 126(3): 449-455, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34811502
4.
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.
Oncologist
; 27(1): e29-e36, 2022 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35305093
5.
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Oncologist
; 26(4): 302-309, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33336844
6.
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study.
Support Care Cancer
; 29(7): 3971-3980, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33392769
7.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 21(4): 497-507, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32164906
8.
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
Br J Cancer
; 123(3): 403-409, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32424148
9.
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.
Oncologist
; 25(3): e460-e468, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162808
10.
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.
Oncologist
; 25(9): 803-809, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32369650
11.
Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials.
Oncologist
; 25(9): 780-786, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32272500
12.
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
BMC Cancer
; 20(1): 683, 2020 Jul 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32698790
13.
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study.
BMC Cancer
; 24(1): 563, 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38711003
14.
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
BMC Cancer
; 19(1): 283, 2019 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-30922323
15.
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma.
Blood Cancer Discov
; 5(2): 106-113, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38194367
16.
The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO).
Tumori
; 110(3): 203-208, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38326240
17.
The Key Role of Patient Empowerment in the Future Management of Cancer-Related Malnutrition.
Nutrients
; 15(1)2023 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36615892
18.
Should we exclude patients with peritoneal carcinosis of colorectal origin and high PCI from CRS + HIPEC?
Updates Surg
; 75(7): 1819-1825, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37423956
19.
Transient receptor potential ankyrin 1 (TRPA1) mediates reactive oxygen species-induced Ca2+ entry, mitochondrial dysfunction, and caspase-3/7 activation in primary cultures of metastatic colorectal carcinoma cells.
Cell Death Discov
; 9(1): 213, 2023 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37393347
20.
Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study.
Cardiooncology
; 9(1): 18, 2023 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37005652